Xilio Therapeutics, Inc. XLO
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Xilio Therapeutics, Inc. (XLO) is a healthcare company listed in the US with a market value of about $57M. In the twelve months to September 30, 2026 it had revenue of $55M and net income of -$11M, a net margin of -20.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -109%.
About Xilio Therapeutics
Xilio Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 327% over three years (dilution for shareholders). It spends 128% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $55M | $44M | $6M | — | — | — | — |
| Net income | -$11M | -$35M | -$58M | -$76M | -$88M | -$76M | -$55M |
| Free cash flow | -$58M | -$6M | -$18M | -$69M | -$78M | -$82M | -$38M |
| EPS (diluted) | $-1.37 | $-4.19 | $-15.24 | $-38.92 | $-45.08 | $-189.28 | $-1475.88 |
| Net margin | -20.9% | -80.0% | -918.1% | — | — | — | — |
| ROIC | — | -99.4% | -235.4% | -126.7% | -56.1% | -28.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Xilio Therapeutics pay a dividend?
Not currently.
Is Xilio Therapeutics a good stock to buy?
We do not give buy or sell advice. Xilio Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.